Many pharmaceutical compounds being developed in recent years are poorly soluble in water. This has led to insufficient oral bioavailability of many compounds in vitro. The amorphous formulation is one of the promising techniques to increase the oral bioavailability of these poorly water-soluble compounds. However, an amorphous drug substance is inherently unstable because it is a high energy form. In order to increase the physical stability, the amorphous drug is often formulated with a suitable polymer to form an amorphous solid dispersion. Previous research has suggested that the formation of an intimately mixed drug-polymer mixture contributes to the stabilization of the amorphous drug compound. The goal of this research is to better understand the role of miscibility, molecular interactions and mobility on the physical stability of amorphous solid dispersions. Methods were developed to detect different degrees of miscibility on nanometer scale and to quantify the extent of hydrogen-bonding interactions between the drug and the polymer. Miscibility, hydrogen-bonding interactions and molecular mobility were correlated with physical stability during a six-month period using three model systems. Overall, this research provides molecular-level insights into many factors that govern the physical stability of amorphous solid dispersions which can lead to a more effective design of stable amorphous formulations.

Not available / text

A growing number of therapeutic compounds currently being developed by pharmaceutical companies are poorly water soluble leading to limited and/or erratic bioavailability. The rate limiting step for absorption of these compounds is dependent on the dissolution and apparent solubility. Nanoparticle formation has been exploited as a method to improve the bioavailability of these poorly water soluble active pharmaceutical ingredients (API) by increasing the dissolution rates and apparent solubilities. The influence of hydrophilic stabilizers in powder compositions prepared by the spray freezing into liquid (SFL) process using either an emulsion feed dispersion or organic co-solvent feed solutions on enhancing the wetting and dissolution properties of nanostructured aggregates containing itraconazole (ITZ). Subsequently, an in vivo pharmacokinetic study was conducted comparing the SFL processed powder to commercial Sporanox®. An ultra-rapid freezing (URF) technology has been developed to produce high surface area powders composed of solid solutions of an active pharmaceutical ingredient (API) and a polymer stabilizer. Rapid freezing technologies are known to enhance the physico-chemical properties of APIs and thus increase bioavailability. However, the effect of the different freezing geometries and rates in the URF process are unknown. Therefore, this study investigated how solvent properties and thin film geometry of the droplet affect the freezing rate and thus the physico-chemical properties of micronized danazol powders. Amorphous nanoparticles containing tacrolimus (TAC) in a solid dispersion were prepared using the Ultra-rapid Freezing (URF) process. The objective of this study was to assess the effects of combinations of polymeric stabilizers on the maximum degree and extent of supersaturation of TAC. An attempt to establish if an in vitro-in vivo correlation exists between supersaturation and improved pharmacokinetic parameters for orally dosed TAC was performed. Enteric solid dispersions could overcome limitations of premature precipitation of supersaturated solutions by 1.) delaying dissolution until the compound enters the intestines where absorption is favored and 2.) increasing the apparent solubility at higher pH to increase the driving force for absorption. The objective of the study is to investigate the influence of composition parameters including drug:polymer ratio and polymer type, and particle structure of enteric solid dispersions on the release of ITZ. / text

N-substituted pantothenamides are analogues of pantothenate, the precursor of the essential metabolic cofactor coenzyme A (CoA). These compounds are substrates of pantothenate kinase (PanK) in the first step of CoA biosynthesis, possessing antimicrobial activity against multiple pathogenic bacteria. This enzyme is an attractive target for drug discovery due to low sequence homology between bacterial and human PanKs. In this study, the crystal structure of the PanK from the multidrug-resistant bacterium Klebsiella pneumoniae (KpPanK) was first solved in complex with N-pentylpantothenamide (N5-Pan). The structure reveals that the N5-Pan pentyl tail is located within a highly aromatic pocket, suggesting that an aromatic substituent may enhance binding affinity to the enzyme. This finding led to the design of N-pyridin-3-ylmethylpantothenamide (Np-Pan) and its co-crystal structure with KpPanK was solved. The structure reveals that the pyridine ring adopts alternative conformations in the aromatic pocket, providing the structural basis for further improvement of pantothenamide-binding to KpPanK.

N-substituted pantothenamides are analogues of pantothenate, the precursor of the essential metabolic cofactor coenzyme A (CoA). These compounds are substrates of pantothenate kinase (PanK) in the first step of CoA biosynthesis, possessing antimicrobial activity against multiple pathogenic bacteria. This enzyme is an attractive target for drug discovery due to low sequence homology between bacterial and human PanKs. In this study, the crystal structure of the PanK from the multidrug-resistant bacterium Klebsiella pneumoniae (KpPanK) was first solved in complex with N-pentylpantothenamide (N5-Pan). The structure reveals that the N5-Pan pentyl tail is located within a highly aromatic pocket, suggesting that an aromatic substituent may enhance binding affinity to the enzyme. This finding led to the design of N-pyridin-3-ylmethylpantothenamide (Np-Pan) and its co-crystal structure with KpPanK was solved. The structure reveals that the pyridine ring adopts alternative conformations in the aromatic pocket, providing the structural basis for further improvement of pantothenamide-binding to KpPanK.

Central infusion of the hexapeptide angiotensin IV (Ang IV) and its analogs have been demonstrated to markedly enhance memory retention and retrieval in rats using a range of learning and memory paradigms. This effect is mediated by the binding of the peptide to the specific binding site previously described as the AT4 receptor. The AT4 receptor has been isolated and identified as insulin-regulated aminopeptidase (IRAP), a type II transmembrane protein belonging to the M1 family of zinc-dependent aminopeptidases. Subsequently, AT4 receptor ligands, including Ang IV and its analogues and the unrelated peptide LVV-hemorphin-7, were demonstrated to be peptide inhibitors of IRAP. These findings suggest that AT4 ligands may exert their cognitive effects by inhibiting the catalytic activity of IRAP in the brain. Therefore, IRAP is an important target for the development of a new class of therapeutic agents for the treatment of memory loss. / To characterize IRAP at the molecular level and identify non-peptide inhibitors of IRAP for drug development, the aims of this study were to: 1) determine whether IRAP exists as a homodimer; 2) identify cysteine residue(s) involved in IRAP dimerization; 3) investigate the roles of the conserved residues of the HEXXH(X)18E Zn2+-binding motif and the GAMEN motif in substrate/inhibitor binding using site-directed mutagenesis; 4) use a molecular model of the catalytic domain of IRAP based on the crystal structure of a related M1 family metallopeptidase to: (i) identify key residues required for substrate/inhibitor binding; (ii) identify and characterize non-peptide IRAP inhibitors from a compound database by in silico virtual screening based on the homology model of IRAP. / Co-immunoprecipitation followed by Western blotting of IRAP under reducing and non-reducing conditions showed IRAP exists both as covalently- and non-covalently-bound homodimers. Serine scanning of cysteine residues potentially involved in forming inter-molecule disulfide-bonds was performed. Mutational analyses indicated that covalent homodimerization of IRAP is due to more than one cysteine residue. Limited trypsin digestion followed by co-immunoprecipitation suggests that non-covalent homodimerization of IRAP involves residues/regions within the last 130 amino acids of the protein. / The catalytic site of IRAP contains two consensus motifs, the H464EXXH468(X)18E487 Zn2+-binding motif and the G428AMEN432 motif. The role of conserved residues with these motifs was investigated using site-directed mutagenesis and pharmacological analyses. The conserved His and Glu residues of the Zn2+-binding motif were shown to be essential for IRAP catalytic activity. This was also observed for the Met and Glu residues of the GAMEN motif, while Asn mutant retained some catalytic activity. Residues important for substrate or inhibitor binding were identified as Gly, Ala and Asn. / A molecular model of the catalytic domain of IRAP based on the crystal structure of a homologous M1 metallopeptidase, leukotriene A4 hydrolase (LTA4H) was used to compare the catalytic sites of IRAP and LTA4H, and identified two amino acids at the putative substrate-binding pocket: Ala427 and Leu483 in IRAP, and the corresponding residues Tyr267 and Phe314 in LTA4H. A mutational analysis involving substitution of Ala427 and Leu483 with the corresponding residues revealed Ala427 and Leu483 characterize the enzyme S1 subsite, influencing the affinity and placement of substrates and peptide inhibitors in the catalytic site. / The molecular model of IRAP was also used for virtual screening of compound databases to identify novel non-peptide inhibitors. After two rounds of in silico screening, a family of compounds was identified and shown to be specific and competitive inhibitors of IRAP. Preliminary results suggest that one of these inhibitors, referred to as HFI 142, may possess memory-enhancing properties. The identification of non-peptide IRAP inhibitors will assist in pharmacological studies aimed at understanding the molecular mechanisms of IRAP aminopeptidase activity and physiological role of IRAP. In addition, the new inhibitors have the potential to form the basis for the development of a novel class of drugs useful for treating memory disorders.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 5 uppsatser.

Bacteria are known to release a large variety of small molecules known as autoinducers (AI) which effect quorum sensing (QS) initiation. The interruption of QS effects bacterial communication, growth and virulence. Three novel classes of S-ribosylhomocysteine (SRH) analogues as potential inhibitors of S-ribosylhomocysteinase (LuxS enzyme) and AI-2 modulators of QS were developed. The synthesis of 2-deoxy-2-bromo-SRH analogues was attempted by coupling of the corresponding 2-bromo-2-deoxypentafuranosyl precursors with the homocysteinate anion. The displacement of the bromide from C2 rather than the expected substitution of the mesylate from C5 was observed. The synthesis of 4-C-alkyl/aryl-S-ribosylhomocysteine analogues involved the following steps: (i) conversion of the D-ribose to the ribitol-4-ulose; (ii) diastereoselective addition of various alkyl or aryl or vinyl Grignard reagents to 4-ketone intermediate; (iii) oxidation of the primary hydroxyl group at C1 followed by the intramolecular ring closure to the corresponding 4-C-alkyl/aryl-substituted ribono-1,4-lactones; (iv) displacement of the activated 5-hydroxyl group with the protected homocysteinate. Treatment of the 4-C-alkyl/aryl-substituted SRH analogues with lithium triethylborohydride effected reduction of the ribonolactone to the ribose (hemiacetal) and subsequent global deprotection with trifluoroacetic acid provided 4-C-alkyl/aryl-SRHs. The 4-[thia]-SRH were prepared from the 1-deoxy-4-thioribose through the coupling of the α-fluoro thioethers (thioribosyl fluorides) with homocysteinate anion. The 4-[thia]-SRH analogues showed concentration dependent effect on the growth on las (50% inhibitory effect at 200 µg/mL). The most active was 1-deoxy-4-[thia]-SRH analogue with sufur atom in the ring oxidized to sulfoxide decreasing las gene activity to approximately 35% without affecting rhl gene. Neither of the tested compounds had effect on bioluminescence nor on total growth of V. harveyi, but had however slight inhibition of the QS.

Os trabalhos realizados e apresentados nesta tese de doutorado compreendem diversos estudos computacionais e experimentais aplicados ao planejamento de candidados a novos fármacos para o tratamento do câncer, de uma metodologia inovadora para investigar a formação de complexos proteicos e de uma base de compostos naturais reunindo parte da biodiversidade brasileira com a finalidade de incentivar e auxiliar a descoberta e o desenvolvimento de novos fármacos no país. No primeiro capítulo, são descritos estudos que permitiram a identificação e o desenvolvimento de novas moléculas com atividade anticâncer, através da integração de ensaios bioquímicos e métodos de modelagem molecular na área de química medicinal. Dessa forma, estudos de modelagem molecular e ensaios bioquímicos utilizando uma base de compostos disponibilizada pela colaboração com o Laboratório de Síntese de Produtos Naturais e Fármacos (LSPNF) da UNICAMP, permitiram identificar uma série de moléculas da classe ciclopenta-β-indóis como inibidores da polimerização de microtúbulos com considerável atividade anti-câncer. Estes compostos apresentaram-se capazes de modular a polimerização de microtúbulos em ensaios in vitro frente ao alvo molecular e a células cancerígenas, com valores de IC50 na faixa de 20 a 30 μM. Além disso, estudos experimentais permitiram identificar o sítio da colchicina na tubulina como a região de interação desta classe e ensaios de migração celular comprovaram sua atividade antitumoral. A partir dos resultados obtidos, estudos mais aprofundados de docagem e dinâmica molecular permitiram elucidar as interações moleculares envolvidas no processo de ligação à proteína tubulina, e a utilização destes modelos moleculares no planejamento, síntese e avaliação de uma nova série de compostos. Com base nos dados obtidos por estudos computacionais, modificações foram propostas e novos inibidores da polimerização de tubulina foram planejados, sintetizados e avaliados, resultando na identificação de um inibidor de elevada atividade e perfil farmacodinâmico superior dentre as moléculas planejadas, com IC50 de 5 μM. Concomitantemente, ensaios de citotoxicidade in vitro demostraram uma interessante seletividade destes compostos por células cancerígenas em comparação a células saudáveis. Os estudos desenvolvidos com inibidores de tubulina aqui apresentados permitiram identificar moduladores da polimerização de microtúbulos com excelente perfil anti-câncer, que servirão como modelo para o desenvolvimento de novos tratamentos eficazes contra o câncer. No segundo capítulo é apresentado um novo método para predizer modificações conformacionais e a formação de complexos multiméricos em sistemas proteicos. Este método foi elaborado durante os estudos desenvolvidos ao longo de um programa de intercâmbio no laboratório The Center for Theoretical and Biological Physics (CTBP, Rice University, Estados Unidos), sob orientação do professor Dr. José Nelson Onuchic. Durante este projeto, estudos de modelagem computacional foram realizados utilizando métodos computacionais modernos desenvolvidos no próprio CTBP, tal como o método de Análise de Acoplamento Direto (DCA, do inglês Direct-Coupling Analysis) e um método de simulação conhecido como Modelagem Baseada em Estrutura (SBM, do inglês Structure-Based Modeling). Nos estudos aqui apresentados, os métodos DCA e SBM desenvolvidos no CTBP foram combinados, modificados e ampliados no desenvolvimento de uma nova metodologia que permite identificar mudanças conformacionais e elucidar mecanismos de enovelamento e oligomerização em proteínas. Os resultados obtidos através da predição de diversos complexos proteicos multiméricos com uma alta precisão mostram que este sistema é extremamente eficaz e confiável para identificar regiões de interface de contato entre proteínas a a estrutura quaternária de complexos macromoleculares. Esta nova metodologia permite a elucidação e caracterização de sistemas proteicos incapazes de serem determinados atualmente por métodos puramente experimentais. No terceiro capítulo desta tese de doutorado, é descrito a construção de uma base virtual de dados em uma iniciativa pioneira que tem como principal objetivo reunir e disponibilizar o máximo possível de toda a informação já obtida através do estudo da biodiversidade brasileira. Esta base, intitulada NuBBE DataBase, reúne diversas informações como estrutura molecular 2D e 3D e informações de atividades biológicas de diversas moléculas já isoladas pelo Núcleo de Bioensaios Biossíntese e Ecofisiologia de Produtos Naturais (NuBBE), localizado na Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP). A NuBBEDB será de grande utilidade para a comunidade científica, fornecendo a centros de pesquisa e indústrias farmacêuticas informações para estudos de modelagem molecular, metabolômica, derreplicação e principalmente para o planejamento e a identificação de novos compostos bioativos. / The work developed during a doctorate program and shown here as a PhD thesis reports the accomplishment of a series of computational and experimental studies focused on the development of new anticancer agents, an innovative methodology for the investigation of protein complexes formation and of a new database for natural products based on the Brazilian biodiversity, in an effort to assist and encourage the discovery and development of new pharmaceutical drugs inside country. The first chapter describes studies that resulted in the identification and development of new molecules with anticancer activity through the integration of biochemical experiments and molecular modeling methods in the area of medicinal chemistry. Thus, molecular modeling studies and biochemical assays using a library of compounds provided by collaboration with the Laboratório de Síntese de Produtos Naturais e Fármacos (LSPNF) from the University of Campinas (Unicamp) have identified a number of molecules of the cyclopenta-b-indole class as inhibitors for microtubule polymerisation, with substantial anti-cancer activity. These compounds showed to be able to modulate microtubule polymerisation on in vitro assays against the molecular target and cancer cells with IC50 values in the range of 20 to 30 μM. Moreover, experimental studies have identified the colchicine site of tubulin as in the region of interaction of this class and cell migration assays have proven their antitumour activity. Based on these results, further studies using molecular docking and molecular dynamics allowed to elucidate the molecular interactions involved in the binding process to tubulin protein, and these molecular models were used to guide the design, synthesis and evaluation of a novel series of compounds. From the data obtained by computational studies, modifications were proposed to design, synthesise and evaluate new tubulin polymerisation inhibitors, resulting in identification of a high-activity inhibitor and superior pharmacodynamic profile and IC50 of 5 μM. Alongside, in vitro cytotoxicity assays demonstrated an interesting selectivity of these compounds for cancer cells when compared to healthy cells. The studies presented here with tubulin inhibitors allowed to identify modulators of microtubule polymerisation with excellent anti-cancer profile, that will provide a valuable scaffold for the development of new effective treatments against cancer. The second chapter presents a new method for predicting changes on the conformational and the formation of multimeric protein complexes. This method was developed during the studies carried out over an exchange program in the Center for Theoretical and Biological Physics (CTBT, Rice University, USA), under the supervision of professor Dr. José Nelson Onuchic. During this project, computer modeling studies were carried using modern methods developed in the CTBT itself, such as Direct-Coupling Analysis (DCA) and a simulation method known as Modeling Based Structure (SBM). In the studies presented here, the DCA and SBM methods developed in CTBP were combined, modified and expanded to develop a new methodology able to identify the conformational changes and to elucidate mechanisms folding and oligomerization of proteins. The results obtained through prediction of various multimeric protein complexes with high accuracy show that this system is extremely effective and reliable to identify interface contacts between proteins and to predict the quaternary structure of macromolecular complexes. This new method allows the characterization and elucidation of protein systems that are currently unable to be solely determined by experimental methods. The third chapter of this doctoral thesis describes the construction of a virtual database in a pioneering initiative that aims to gather and make available all the information already obtained through the study of Brazilian biodiversity. This database, entitled NuBBE DataBase, brings together various information such as 2D and 3D molecular structure and biological activity of several molecules already isolated by the Núcleo de Bioensaios Biossíntese e Ecofisiologia de Produtos Naturais(NuBBE), located at the Universidade Estadual Paulista Julio de Mesquita Filho (UNESP). The NuBBEDB will be useful to the scientific community, providing research and pharmaceutical centers information for molecular modeling studies, metabolomics, derreplication and principally for the planning and identification of new bioactive compounds.

A Doença de Chagas, causada pelo parasita Trypanosoma cruzi, atinge cerca de um quarto da população da América Latina. Os fármacos disponíveis para o tratamento desta doença são inapropriados, apresentam baixa eficácia e sérios efeitos colaterais que limitam o seu uso. Esse grave panorama torna urgente a descoberta de novos agentes quimioterápicos para o tratamento seguro e eficaz da doença. A via glicolítica é principal forma de obtenção de energia de tripanosomatídeos. Um alvo molecular atrativo desta via bioquímica que desempenha papel essencial no controle do fluxo glicolítico do Trypanosoma cruzi, a enzima gliceraldeído-3-fosfato desidrogenase (GAPDH), foi selecionada neste trabalho de Tese para estudos em biologia estrutural e química medicinal visando à identificação e planejamento de novos inibidores enzimáticos. Neste contexto, triagens biológicas resultaram na identificação de compostos de origem natural e sintética com atividade inibitória in vitro frente à GAPDH de T. cruzi, ampliando a diversidade química de moduladores seletivos deste alvo. Estudos cinéticos e estruturais demonstraram o comportamento não cooperativo entre os sítios ativos da enzima GAPDH de T. cruzi em relação à interação com o cofator NAD+, fornecendo importantes evidências mecanísticas e estruturais para uma melhor compreensão das bases moleculares envolvidas no processo de reconhecimento molecular. Os estudos das relações quantitativas entre a estrutura e atividade (QSAR 2D e QSAR 3D) resultaram na geração de modelos com elevada consistência estatística interna e externa, além de alto poder preditivo da propriedade-alvo. Além disso, estudos de modelagem molecular e de QSAR 3D revelaram aspectos estruturais relevantes para o planejamento de inibidores seletivos da enzima GAPDH de tripanosomatídeos. Por fim, uma estratégia de triagem virtual baseado na estrutura do receptor foi empregada para a identificação de novos inibidores da GAPDH de T. cruzi, consistindo, entre outros, na aplicação de filtros hierárquicos sucessivos envolvendo restrições farmacofóricas e estudos de docagem molecular que resultaram na seleção de 35 candidatos a inibidores da enzima-alvo. Os trabalhos integrando estudos em química medicinal e biologia estrutural apresentados nessa Tese de Doutorado significam importantes contribuições no desenvolvimento de bases científicas sólidas para o planejamento de novos inibidores potentes e seletivos da enzima GAPDH de T. cruzi, um alvo molecular de alta prioridade em nosso grupo de pesquisa. / Parasitic diseases are the foremost threat to human health and welfare around the world. Chagas\' disease (also called American trypanosomiasis) is a tropical parasitic disease which occurs in Latin America, particularly in South America. The currently available drugs for this parasitic disease have severe limitations, including poor efficacy and high toxicity. The crucial dependence of trypanosomatids on glycolysis as a source of energy makes the glycolytic enzymes promising targets for drug design. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from Trypanosoma cruzi, a key enzyme in the glycolytic cascade, has been selected as an attractive drug target in this PhD Thesis work for studies in structural biology and medicinal chemistry for the identification and design of new enzyme inhibitors. In this context, compounds from both natural and synthetic sources with in vitro inhibitory activity against T. cruzi GAPDH were identified by screening assays, improving the chemical diversity of selective modulators of the target. Kinetic and structural studies have demonstrated the non-cooperative behavior between the T. cruzi active sites in the interaction with the NAD+ cofactor, shedding some light on the mechanistic and structural determinants underlying the biochemical recognition phenomenon. Quantitative structure-activity relationships (2D QSAR 2D and 3D QSAR) were successfully created, resulting in statistically significant models with good predictive ability for untested compounds. In addition, molecular modeling and 3D QSAR studies highlighted important structural aspects to assist the design of novel trypanosomatid GAPDH inhibitors. Finally, a structure-based virtual screening approach was employed for the identification of novel inhibitors of T. cruzi GAPDH, consisting of several consecutive hierarchical, fast pharmacophore matching and molecular docking, which afforded 35 inhibitor candidates for the target enzyme. The integration of structural biology and medicinal chemistry studies presented in this PhD Thesis are important contributions in the development of strong scientific basis for the design of new selective and potent inhibitors of GAPDH from T. cruzi, a molecular target of highest priority in our research group.